<DOC>
	<DOCNO>NCT00362856</DOCNO>
	<brief_summary>There therapeutic product market celiac disease today . Current treatment limit gluten free food gluten-free diet . The main purpose study test safe , efficacious tolerable study drug AT1001 subject diagnose celiac disease . A second purpose study body respond drug ingest gluten . This response determine test urine , capture daily weekly gastrointestinal symptom associate celiac disease .</brief_summary>
	<brief_title>Safety Tolerability Study AT1001 Celiac Disease Subjects</brief_title>
	<detailed_description />
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Must diagnose celiac disease biopsy ≥ 6 month ( attend physician confirmation accept lieu biopsy report ) . Have AntiTissue Transglutaminase ( tTG ) ≤ 10 EU measure serology . Must glutenfree diet least past 6 month . Have chronic active GI disease celiac disease ( e.g. , IBS , Crohn 's , Colitis ) . Have diabetes ( Type 1 Type 2 ) . Chronically consume nonsteroidal antiinflammatory agent ( `` NSAIDs '' ) take protonpump inhibitor . Consuming oral corticosteroid immune suppressant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2007</verification_date>
</DOC>